Analyst Ratings January 29, 2026

KeyBanc Lowers Microsoft Price Target to $600 Citing Azure Growth Headwinds

Analyst keeps Overweight stance even as cloud growth and GPU allocation raise near-term concerns

By Hana Yamamoto MSFT
KeyBanc Lowers Microsoft Price Target to $600 Citing Azure Growth Headwinds
MSFT

KeyBanc has reduced its 12-month price objective for Microsoft to $600 from $630 while retaining an Overweight rating, citing weaker-than-expected Azure constant currency growth and an outlook the firm described as "even less inspiring." The bank also flagged a shift in GPU resource priorities toward Microsoft’s first-party AI offerings such as Copilot, creating a short-term trade-off that may weigh on Azure revenue growth. Microsoft, meanwhile, reported stronger-than-expected fiscal second-quarter results with EPS and revenue beats, and other firms including Truist and Raymond James maintained favorable ratings despite the cloud concerns.

Key Points

  • KeyBanc lowered its Microsoft price target to $600 from $630 but kept an Overweight rating; target implies upside versus the $481.63 stock price.
  • Azure reported weaker-than-expected constant currency growth and KeyBanc said the next-quarter outlook was "even less inspiring," creating near-term concern for cloud revenue expansion - impacts cloud computing and enterprise software sectors.
  • Microsoft beat fiscal Q2 2026 estimates with EPS of $4.14 and revenue of $81.3 billion; Truist reiterated Buy citing significant commercial bookings growth and a $625 billion commercial remaining performance obligation.

KeyBanc has trimmed its price target on Microsoft to $600.00 from $630.00 while keeping an Overweight rating on the shares. The revised target implies material upside relative to Microsoft’s most recent price of $481.63, and the company retains a "GREAT" overall financial health score according to InvestingPro data.

The adjustment from KeyBanc follows Azure delivering constant currency growth that fell short of market expectations. The research firm characterized the next quarter’s outlook for the cloud business as "even less inspiring," highlighting a near-term softness in demand or execution versus what investors had anticipated.

Despite these concerns at the platform level, Microsoft’s broader top-line momentum remains solid. The company has recorded overall revenue growth of 15.59% over the last twelve months, underscoring persistent underlying demand across its product set.

Previously, KeyBanc had pointed to capacity constraints as the primary limiter on Azure revenue growth. In its latest assessment, however, the firm flagged a new, internal prioritization issue: first-party AI initiatives appear to be receiving greater access to GPU capacity than third-party or enterprise cloud workloads.

KeyBanc noted that Microsoft’s first-party AI applications such as Copilot and internal research appear to be receiving higher priority in "the GPU pecking order" than previously anticipated.

The research house described this dynamic as creating a "short-term, long-term trade off." In its view, "the short-term pain is real," as some Azure customers or workloads may face delayed or constrained access to GPU resources. At the same time, KeyBanc expressed uncertainty about whether prioritizing internal AI projects will deliver the expected payoff over the longer horizon.

Microsoft’s most recent fiscal results offer a mixed backdrop to these analyst concerns. For the fiscal second quarter of 2026 the company reported earnings per share of $4.14, ahead of the $3.93 analysts had forecast, and revenue of $81.3 billion, surpassing the $80.23 billion estimate. Those beats point to continued execution across several business lines even as certain cloud metrics soften.

Truist Securities has reiterated its Buy rating on Microsoft, drawing attention to strong commercial demand and a dramatic increase in bookings. The firm highlighted that bookings rose by more than 230% year-over-year and noted a commercial remaining performance obligation of $625 billion, a metric it views as evidence of durable enterprise demand.

Other analysts have also updated their valuations in light of the quarter. Raymond James moved its price objective to $580 from $600 while maintaining an Outperform rating. That change explicitly followed Microsoft’s fiscal second-quarter report and reflected concerns that Azure’s growth and guidance were slightly below investor expectations.

Overall, the market is balancing Azure-specific headwinds tied to growth and GPU allocation with signs of resilient revenue and earnings performance across the company. Analysts differ in their near-term outlooks and in how they weigh potential long-term benefits from Microsoft’s prioritization of first-party AI investments.


What this means for markets and sectors

  • Cloud computing - Azure growth dynamics and resource allocation are the immediate focus for investors.
  • Enterprise software and AI - Prioritization of first-party AI applications could influence enterprise customers and the competitive landscape for AI services.
  • Semiconductors/GPU supply chains - Shifts in GPU allocation within a large cloud provider may have ripple effects across hardware demand and vendor relationships.

Risks

  • GPU resource prioritization - KeyBanc warned that Microsoft’s allocation of GPU capacity to first-party AI projects like Copilot could constrain Azure growth in the short term; this risk affects cloud computing customers and AI service buyers.
  • Near-term Azure demand and guidance - Azure’s constant currency growth and a less encouraging near-term outlook introduce uncertainty for investors and may weigh on valuation assumptions in the technology sector.
  • Execution versus long-term payoff - KeyBanc described a "short-term, long-term trade off," acknowledging tangible short-term pain with unclear long-term benefits from prioritizing internal AI development; this creates uncertainty for enterprise software and AI investment theses.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026